Bevacizumab and Breast Cancer : A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
Joint Authors
Piccart-Gebhart, Martine
Paesmans, Marianne
Rossari, José R.
Metzger-Filho, Otto
de Azambuja, Evandro
Saini, Kamal S.
Gennari, Alessandra
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-09-12
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
Randomized studies have shown different magnitude of bevacizumab benefit in the treatment of advanced breast cancer.
Regulatory agencies have modified bevacizumab treatment indications across different regions.
In this study, we perform a meta-analysis of phase III studies aiming to interrogate the magnitude of bevacizumab benefit for the treatment of first-line HER2-negative metastatic breast cancer (MBC).
Methods.
Data from studies E2100, AVADO and RIBBON-1 were used to calculate the benefit of bevacizumab in terms of tumor overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and toxicities.
Combined statistical estimates of hazard ratios (HR) and odds ratios were calculated using fixed-effects or random-effects models.
Results.
A total of 2,695 patients were evaluated.
Combining bevacizumab with different chemotherapy backbones resulted in a 30% risk reduction of PFS events (HR = 0.70; 95% confidence interval [CI], 0.57–0.86) and increased ORR (odds ratio 1.81; 95% CI, 1.53–2.14).
No OS benefit could be demonstrated (HR = 0.95; 95% CI, 0.85–1.06).
Bevacizumab significantly increased the incidence of adverse events such as proteinuria, hypertension and cardiovascular events.
Conclusions.
Bevacizumab combined with chemotherapy in the first-line treatment of MBC significantly improved ORR and PFS, but also increased grade 3-4 toxicities.
No significant OS advantage was observed.
American Psychological Association (APA)
Rossari, José R.& Metzger-Filho, Otto& Paesmans, Marianne& Saini, Kamal S.& Gennari, Alessandra& de Azambuja, Evandro…[et al.]. 2012. Bevacizumab and Breast Cancer : A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. Journal of Oncology،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-470563
Modern Language Association (MLA)
Rossari, José R.…[et al.]. Bevacizumab and Breast Cancer : A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. Journal of Oncology No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-470563
American Medical Association (AMA)
Rossari, José R.& Metzger-Filho, Otto& Paesmans, Marianne& Saini, Kamal S.& Gennari, Alessandra& de Azambuja, Evandro…[et al.]. Bevacizumab and Breast Cancer : A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. Journal of Oncology. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-470563
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-470563